グラウコマの病理生理学と治療:レビュー
Robert N Weinreb1, Tin Aung2, Felipe A Medeiros1
1Hamilton Glaucoma Center, Shiley Eye Center and Department of Ophthalmology, University of California, San Diego, La Jolla.
JAMA
|May 15, 2014
まとめ
視力喪失の主な原因であるグラウコマは,早期発見が必要です. プライマリケア医は,開角および閉角緑内障の診断と治療の遵守を支援することができます.
科学分野:
- オフタルモロジック (眼科)
- 公衆衛生は公衆衛生である.
背景:
- グラウコマは,世界中で不可逆的な失明の主な原因です.
- 遅れた診断は,無症状の進行のために一般的です.
研究 の 目的:
- 開角性および閉角性緑内障の病理生理学および治療に関する現在の証拠をレビューする.
- グラウコマの管理について,初等医療従事者に知らせる.
主な方法:
- MEDLINE,コクラン図書館,参考文献の文献検索.
- グラウコマの病理生理学と治療に関する2000年から2013年の英語の研究が含まれています.
- プライマリケアに係る関連性から選択された210件の記事.
主要な成果:
- グラウコマは,進行的な光神経病変と網膜のガンジオン細胞変性を含む.
- 眼内圧の低下が主要な治療戦略である.
- 治療には,眼性低血圧ドロップ,レーザー・トラベキュロプラスティ,手術などがあります.
結論:
- プライマリケア医師は,眼科の紹介のためにリスクのある患者を特定することができます.
- 医者は,薬の投与順守を促進し,副作用を管理することによって,結果を向上させることができます.
関連する概念動画
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
861
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
861
Ophthalmic Drug Delivery Systems
282
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
282
Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K


